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ART ICLE Open Ac ce s s
HCV-associated exosomes promote
myeloid-derived suppressor cell expansion
via inhibiting miR-124 to regulate T
follicular cell differentiation and function
Lin Wang1,2,3, Dechao Cao1,2, Ling Wang1,2, Juan Zhao1,2, Lam Nhat Nguyen1,2, Xindi Dang1,2, Yingjie Ji1,2,4,
Xiao Y. Wu1,2, Zheng D. Morrison1,2, Qian Xie1, Mohamed El Gazzar1, Shunbin Ning1,2, Jonathan P. Moorman1,2,5 and
Zhi Q. Yao1,2,5
Abstract
Virus-infected cells can regulate non-permissive bystander cells, but the precise mechanisms remain incompletely
understood. Here we report that this process can be mediated by transfer of viral RNA-loaded exosomes shed from
infected cells to myeloid-derived suppressor cells (MDSCs), which in turn regulate the differentiation and function of
T cells during viral infection. Specifically, we demonstrated that patients with chronic hepatitis C virus (HCV) infection
exhibited significant increases in T follicular regulatory (TFR) cells and decreases in T follicular helper (TFH) cells. These
MDSC-mediated T-cell dysregulations resulted in an increased ratio of TFR/TFH and IL-10 production in peripheral
blood. Specifically, co-culture of MDSCs derived from HCV patients with healthy peripheral blood mononuclear cells
(PBMCs) induced expansion of TFR, whereas depletion of MDSCs from PBMCs of HCV patients reduced the increases in
TFR frequency and IL-10 production, and promoted the differentiation of IFN-γ-producing TFH cells. Importantly, we
found that exosomes isolated from the plasma of HCV patients and supernatant of HCV-infected hepatocytes could
drive monocytic myeloid cell differentiation into MDSCs. These exosomes were enriched in tetraspanins, such as CD63
and CD81, and contained HCV RNA, but exosomes isolated from patients with antiviral treatment contained no HCV
RNA and could not induce MDSC differentiation. Notably, these HCV RNA-containing exosomes (HCV-Exo) were
sufficient to induce MDSCs. Furthermore, incubation of healthy myeloid cells with these HCV-Exo inhibited the
expression of miR−124, whereas reconstitution of PBMCs with miR−124 abolished the effects of HCV−Exo on MDSC
induction. Taken together, these results indicate that HCV-associated exosomes can transfer immunomodulatory viral
RNA from infected cells to neighboring immune cells and trigger MDSC expansion, which subsequently promotes TFR
differentiation and inhibits TFH function. This study reveals a previously unrecognized path that represents a novel
mechanism of immune dysregulation during chronic viral infection.
Introduction
Hepatitis C virus (HCV) is a blood-borne pathogen
characterized by a high rate (>80%) of chronic hepatitis,
which can progress to liver cirrhosis and hepatocellular
carcinoma—a leading cause for liver transplantation1,2.
Notably, HCV has evolved numerous strategies to evade
host immunity and harness virus persistence;1,2 thus, it
has become an excellent model to study the mechanisms
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of virus-mediated host immune dysfunction and virus
chronicity in humans. While the use of direct-acting
antiviral (DAA) agents can efficiently clear HCV in the
majority of infected individuals, this therapeutic cocktail
faces new issues such as viral mutation, relapse and
reinfection following therapy3,4. According to CDC
(Centers for Disease Control and Prevention) reports, the
number of HCV-related deaths reached an all-time high,
surpassing 60 other nationally reportable infectious
conditions combined, making hepatitis C the number one
reportable infectious disease that kills people in the
United States5. Similar to the issues inherent to HCV,
the failure of the host to successfully manage many
chronic infectious diseases, and to effectively respond to
vaccines in the setting of viral infection, stem from our
incomplete understanding of the pathogen–host interac-
tions that can dampen host immunity and permit viral
persistence.
CD4 T cells are central regulators of pathogen-specific
immunity and vaccine response. They provide help to
cytotoxic CD8 T cells and regulate humoral immune
responses through interaction with B cells, but they can
also participate in immunopathology directly via secretion
of pro- and/or anti-inflammatory cytokines6. This func-
tional versatility is achieved through differentiation of
CD4 T cells into different lineages, such as T helper 1
(TH1), T helper 2 (TH2), T helper 17 (TH17), T follicular
helper (TFH) and T regulatory (Treg) cells, including T
follicular regulatory (TFR) cells
6. While it is believed that
specific immunological context critically influences the
fate of T-cell differentiation, the precise mechanisms that
drive T-cell lineage decisions and their roles in virus
clearance or persistence remain largely unknown.
Myeloid-derived suppressor cells (MDSCs) are a het-
erogeneous population of immature myeloid cells that are
generated due to aberrant myelopoiesis under various
pathological conditions, such as cancer, inflammatory and
infectious diseases7–9. These cells have gained special
attention recently due to their potential to suppress
immune responses, in particular, to induce regulatory
T cells and to suppress the functions of effector
T cells10,11. While MDSCs may contribute to immune
homeostasis after infection via limiting excessive inflam-
matory processes, their expansion may be at the expense
of pathogen elimination, and thus lead to persistent
infection9. We and others have recently reported that
MDSC expansion can inhibit T-cell functions by pro-
moting Treg induction in multiple disease models,
including chronic HCV/HIV infection12–26. However, the
mediators that cause the expansion of MDSCs in the
setting of chronic viral infection remain unclear. In
addition, the role of MDSCs in regulating the differ-
entiation and function of T follicular cells, an important
subset of CD4 T cells that are responsible for regulation of
antigen-specific B cell (vaccine) responses in the setting of
HCV infection, has not been defined.
Exosomes are cell-derived, membrane-enclosed extra-
cellular microvesicles (30–100 nm)27,28. Although the phy-
siological function of exosomes remains unclear, these cell-
released microvesicles have been implicated in serving as
natural carriers to transfer materials (such as antigens,
cytokines, messenger RNA (mRNA) or microRNAs (miR-
NAs)) among cells without direct cell-to-cell contact29–31.
Mounting evidence suggests that exosomes have specialized
functions and play a key role in processes such as inter-
cellular signaling and immune regulation32,33. Notably, the
human tetraspanin CD81 is enriched in exosomes and
functions as the receptor for HCV E2 glycoprotein34,35.
Indeed, HCV genomic materials can be released from
infected hepatocytes into peripheral blood in the form of
circulating exosomes, and these molecules can exploit the
fusogenic capabilities of the exosomes with other cells to
transmit HCV infection and to trigger plasmacytoid
dendritic cell (pDC)-mediated innate immunity, even in
the presence of neutralizing antibodies36–39. Whether HCV-
associated exosomes (HCV-Exo) can induce MDSC
expansion and contribute to T-cell dysregulation and viral
persistence remains unknown.
To further investigate the characteristics of exosomes
and their roles in MDSC, TFH and TFR dysregulation in
HCV pathogenesis, we characterized the nature of HCV-
Exo and their capacity in inducing MDSC expansion and
T-cell dysfunction. We provide evidence that exosomes
isolated from HCV-infected patients, but not DAA-
treated subjects, carry HCV RNA and can induce
MDSC expansion via inhibiting miR−124, which in turn
promotes TFR differentiation and interleukin-10 (IL-10)
production. Depletion of MDSCs from peripheral blood
mononuclear cells (PBMCs) of HCV-infected patients
could reduce this aberrant TFR and IL-10 induction, and
promote TFH cells to produce interferon-γ (IFN-γ). This
study illustrates a novel mechanism of immune dysregu-
lation during chronic viral infection.
Results
Phenotypic and functional characteristics of TFR and TFH
cells in chronic HCV infection
CD4+CXCR5+ T follicular cells are an important subset
of T cells involved in germinal center formation and
regulation of the humoral immune responses40. While
recent studies in humans have improved our under-
standing of TFH cell biology
41–43, the cell frequency,
cytokine profile and their role in HCV infection remain
controversial44,45. The discrepancy of these results is likely
due to the different markers and methods used (e.g., using
PD-1 or CXCR3 in addition to the CD4 and CXCR5) by
different investigators to test HCV patients with different
disease stages. Interestingly, recent studies have shown
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that CD4+CXCR5+ T follicular cells can be further clas-
sified into TFR (CD4
+CXCR5+Foxp3+) and TFH
(CD4+CXCR5+Foxp3−), depending on the level of fork-
head box protein 3 (Foxp3) expression. To further define
the role of these subsets of T cells in chronic HCV
infection, we analyzed the cell frequency, cell ratio and
cytokine secretion of TFH and TFR in the peripheral blood
of HCV-infected individuals versus healthy subjects (HS).
As shown in Fig. 1a (representative dot plots of the gating
strategy) and Fig. 1b (summary data of the flow cyto-
metry), the frequencies of CD4+CXCR5+ T follicular
cells, under both unstimulated and anti-CD3/CD28-sti-
mulated conditions, were slightly lower in PBMCs derived
from chronically HCV-infected patients compared to age-
matched HS, with no statistical difference. The analysis of
Foxp3 expression in CD4+CXCR5+ subsets under both
unstimulated and TCR-stimulated conditions revealed
significant increases in TFR cells (Fig. 1c), and con-
comitant decreases in TFH cells (Fig. 1d) in HCV-infected
patients compared to HS. Notably, HCV patients who
received DAA treatment restored TFR and TFH cell fre-
quencies after achieving sustained virological response
(SVR). In addition, HCV-infected patients exhibited a
significant increase in TFR/TFH ratio in peripheral blood,
which could be completely reversed by the DAA treat-
ment (Fig. 1e).
To characterize the function of T follicular cells during
HCV infection, we analyzed the intracellular cytokine
expression in CD4+CXCR5+ T cells by flow cytometry
following phorbol myristate acetate and kanamycin
Fig. 1 Phenotypic and functional characterization of TFR and TFH cells in HCV patients. a Representative dot plots analysis of TFR and TFH cells by
flow cytometry. PBMCs were first gated on lymphocytes, and then T follicular cells (CD4+CXCR5+), followed by gating the Foxp3 marker to
differentiate TFR (CD4
+CXCR5+Foxp3+) and TFH (CD4
+CXCR5+Foxp3−) cells, respectively. The values in the quadrants indicate the percentages of the
related subsets. b Summary data for the percentage of T follicular cell (CD4+CXCR5+) frequencies in HS (n= 12) versus chronically HCV-infected
patients (n= 16), in both unstimulated and TCR-stimulated conditions. c Summary data for the percentage of Foxp3+ cells in CD4+CXCR5+ cells in
HS (n= 12) versus HCV-infected patients (n= 16) versus DAA-treated HCV subjects with SVR (n= 8) in freshly isolated and TCR-stimulated PBMCs.
d Summary data for the percentage of Foxp3− cells in CD4+CXCR5+ cells in HS versus HCV-infected patients versus DAA-treated subjects with SVR in
freshly isolated and TCR-stimulated PBMCs. e The ratio of TFR/TFH cells in HS versus HCV versus SVR in freshly isolated and TCR-stimulated PBMCs.
f Representative dot plots and summary data for IL-21 expression in CD4+CXCR5+ T follicular cells. g Pooled data of IL-10 expression in CD4+CXCR5+
T follicular cells from HCV patients (n= 13) normalized by HS (n= 12). Each symbol represents an individual subject, and the horizontal bars represent
median with interquartile. P value with significant difference is shown in each panel; NS no significance
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ex vivo stimulation for 5 h. Interestingly, while no sig-
nificant difference in IL-21 production was observed
(Fig. 1f), a significant increase in IL-10 production was
detected in CD4+CXCR5+ T follicular cells derived from
HCV patients versus HS (Fig. 1g). These results suggest
that chronic HCV infection is associated with a decrease
in TFH cells with relatively low IL-21 expression on a per-
cell basis and an increase in TFR cells with remarkably
elevated IL-10 production. However, no correlations were
found among the TFH and TFR cell frequencies or their
cytokine productions with HCV genotype and viral load
in chronically HCV-infected patients (data not shown).
MDSCs inhibit TFH cell function and promote TFR cells
during chronic HCV infection
We have recently shown an expansion of MDSCs dur-
ing chronic HCV and HIV infections, which could inhibit
T-cell function (IFN-γ production) via promoting Treg
differentiation20,25. Since TFR is a specialized subset of
Treg, we hypothesized that the observed increases in TFR
might be due to the expansion of MDSCs in chronic viral
infection. To test this hypothesis, we simultaneously
examined the frequencies of MDSC, TFR and TFH cells in
PBMCs from 9 HCV-infected patients and then analyzed
their associations by Pearson's correlation. As shown in
Fig. 2a, there was a clear positive correlation between
MDSC and TFR cell frequencies in PBMCs derived from
HCV-infected patients. Additionally, the percentage of
MDSCs positively correlated with the ratio of TFR/TFH in
PBMCs of HCV patients. However, there was no corre-
lation between MDSC and TFH cell frequencies in PBMCs
of HCV patients (data not shown). To further clarify
the relationship between MDSCs and TFR/TFH cells, we
purified CD33+ myeloid cells from HCV-infected
patients and incubated them with healthy PBMCs for
3 days, followed by measuring the percentage of
Fig. 2 MDSCs from HCV patients promote Foxp3+ TFR cell differentiation and suppress IFN-γ expression by Teff cells. a Correlation of MDSCs
with TFR/TFH cells in peripheral blood of HCV patients. The frequencies of MDSC (CD14
+CD33+HLA-DR−), TFR (CD4
+CXCR5+Foxp3+) and TFH
(CD4+CXCR5+Foxp3−) cells in PBMCs of 9 HCV-infected patients were simultaneously examined by flow cytometry, and then analyzed by Pearson
Correlation. R and P values are shown above the summary data. b CD33+ myeloid cells from HCV patients induce TFR cell generation. Healthy PBMCs
were co-cultured with or without CD33+ myeloid cells derived from HCV patients for 5 days, followed by flow cytometric analysis for the percentage
of TFR cell (CD4
+CXCR5+Foxp3+) frequency in lymphocytes. c Reducing TFR cells, but not TFH cells, by depletion of CD33
+ myeloid cells from PBMCs
derived from HCV patients. HCV-derived PBMCs, with or without MDSC depletion, were cultured in vitro for 5 days, followed by flow analysis for
CD4+CXCR5+Foxp3+ TFR and CD4
+CXCR5+Foxp3− TFH cells. d Representative dot plots and summary data of flow cytometric analysis of IFN-γ
production by CD4+ cells in PBMCs with or without CD33+ myeloid cell depletion. e Depletion of CD33+ myeloid cells from PBMCs of HCV patients
improves IFN-γ production by T follicular cells, TFR and TFH cells. HCV PBMCs, with or without CD33
+ myeloid cell depletion, were cultured ex vivo in
the presence of stimulation for 5 days, followed by immune staining and flow analysis for IFN-γ production by CD4+CXCR5+ T follicular cells as well
as CD4+CXCR5+Foxp3+ TFR and CD4
+CXCR5+Foxp3− TFH cells. f Depletion of CD33
+ myeloid cells from PBMCs of HCV patients reduces IL-10
production by T follicular cells and TFR cells, but not by TFH cells. PBMCs isolated from chronic HCV patients, with or without depletion of CD33
+
myeloid cells, were cultured ex vivo in the presence of anti-CD3/CD28 stimulation, followed by flow cytometric analysis for IL-10 expression in
CD4+CXCR5+ T cells as well as CD4+CXCR5+Foxp3+TFR and CD4
+CXCR5+Foxp3− TFH cells. P values are shown above each panel
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CD4+CXCR5+Foxp3+ TFR frequencies within lympho-
cytes. As shown in Fig. 2b, co-culture of HCV-derived
CD33+ myeloid cells with healthy PBMCs resulted in a
significant increase in TFR induction compared with
healthy PBMCs cultured without HCV MDSCs. In con-
trast, depletion of CD33+ myeloid cells from HCV
PBMCs resulted in a significant decrease in TFR cells, but
not TFH cells, compared with the HCV PBMCs cultured
with MDSCs (Fig. 2c). These results are in line with our
finding that there is a clear correlation between MDSC
and TFR cells, but not TFH cells, in the peripheral blood of
HCV patients. As we had previously reported20,25,
removal of MDSCs from HCV PBMCs enhanced overall
CD4 T effector cell function, as evidenced by the sig-
nificant increases in IFN-γ production in total CD4+
T cells (Fig. 2d). Furthermore, depletion of MDSCs from
HCV PBMCs led to a significant increase in IFN-γ
secretion in CD4+CXCR5+ T follicular cells, as well as in
TFR and TFH cells (Fig. 2e). Moreover, depletion of
MDSCs from HCV PBMCs led to a significant reduction
in IL-10 expression in CD4+CXCR5+ T follicular cells
and in TFR cells, but not in TFH cells (Fig. 2f). Taken
together, these results suggest that HCV-associated
MDSCs can increase TFR cell number and inhibit the
function of TFH cells during chronic viral infection.
HCV-Exo induce MDSC expansion
We and others have recently reported a significant
expansion of monocytic MDSCs (M-MDSCs) in chronic
HCV infection;21–25 however, the factors that cause
MDSC expansion during HCV infection remain unclear.
Exosomes are small membrane vesicles released into the
extracellular milieu by many cell types; they have fuso-
genic capability to transfer materials among cells, and are
capable of regulating immune responses without direct
cell–cell contact26–34. Thus, we determined whether
exosomes isolated from the plasma of HCV patients can
induce the expansion of MDSCs. We first investigated
whether the exosomes can gain access into the myeloid
cells. To this end, exosomes were isolated from HCV
plasma, labeled with carboxyfluorescein succinimidyl
ester (CFSE) and incubated with healthy CD33+ myeloid
cells for 1 h, followed by flow cytometric and confocal
microscopy analyses. As shown in Fig. 3a, the majority of
CD33+ cells incubated with the CFSE-labeled exosomes
showed fluorescence signal. The presence of CFSE-labeled
exosomes in the CD33+ myeloid cells was confirmed by
confocal microscopy (Fig. 3b).
We then determined whether HCV-Exo have any bio-
logical effect on the blood cells. To this end, exosomes
were isolated from the plasma of 5 HCV-infected patients,
5 age-matched HS and 5 DAA-treated patients with SVR,
incubated with healthy PBMCs for 3 days and subjected to
flow cytometry to measure MDSC expansion. As shown
in Fig. 3c (the gating strategy for CD14+CD33+HLA-DR
− MDSCs) and Fig. 3d (summary data of the percentage
of MDSCs in PBMCs exposed to exosomes), HCV-Exo
significantly induced M-MDSC differentiation compared
to HS-Exo, whereas there was no difference in MDSC
induction by exosomes isolated from HS and DAA-
treated patients with SVR, suggesting a role for active
HCV infection in exosome-mediated MDSC induction.
We also analyzed the effect of exosomes on TFR and TFH
differentiation with PBMCs under the same treatment.
However, we did not observe any direct effect of HCV-
Exo on TFR and TFH differentiation (Fig. 3e), suggesting
that the observed T-cell dysregulation may be due to a
secondary effect from exosomes on MDSCs, rather than
on T cells within such a short period of exposure time as
modeled in this system.
To further examine the kinetic changes of MDSC
induction by HCV-Exo, we incubated PBMCs with exo-
somes at varying concentrations for different times, and
then analyzed by flow cytometry for the frequencies of
CD14+CD33+ monocytic myeloid cells (M-MCs) as well
as CD14+CD33+HLA-DR− M-MDSCs. As shown in
Fig. 3f, after 3–5 days in culture, HCV-Exo increased the
numbers of both M-MCs and M-MDSCs in a time- and
dose-dependent manner compared to the controls treated
with HS-Exo. Since chronically HCV-infected patients
often have other medical conditions (such as diabetes
mellitus, rheumatoid arthritis) which may affect the host
immunity and confound the results, we also assessed the
effect of exosomes isolated from the culture supernatant
of HCV-infected versus non-infected Huh7 hepatocytes
on healthy PBMCs. As shown in Fig. 3g, a significant
expansion of CD14+CD33+ M-MCs was observed when
PBMCs were incubated with exosomes derived from
HCV+ Huh7R compared to HCV− Huh7 cells. Together,
these results suggest that HCV-Exo can be taken up by
myeloid cells to induce MDSC expansion during viral
infection.
HCV-Exo contain HCV RNA
Since exosomes are enriched in CD81, the receptor for
HCV E2 envelope protein, we hypothesized that HCV-
infected hepatocytes may shed viral particles into the
patient plasma in the form of exosomes to act as natural
carriers to transfer HCV RNA from infected hepatocytes
to blood cells. To test this possibility, we isolated exo-
somes from the plasma of HCV-infected patients and HS.
We first characterized the nature of purified exosomes for
the presence of their markers, CD63 and CD81, using
immunoblotting. As shown in Fig. 4a, CD63 (a glycosy-
lated protein of 30–60 kDa) and CD81 (22–26 kDa) bands
were detected in HS-Exo as well as HCV-Exo. Since
exosomes from HCV patients have been shown to
transmit HCV infection via viral RNA in complex with
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heat shock protein 90 (HSP90) and miRNA38, we mea-
sured HSP90, which was found to be positively expressed
in HS-Exo as well as HCV-Exo. We further measured
multiple miRNAs, including miR−124, miR-125 and miR-
29, which were shown to be significantly dysregulated in
CD33+ myeloid cells during HCV infection26, but their
levels did not differ in HS-Exo and HCV-Exo (data not
shown). Notably, these plasma-derived exosomes, as well
as those purified from the supernatants of cultured Huh7
hepatocytes, were significantly enriched in tetraspanins, as
evidenced by stronger CD63 bands compared to the same
amount of plasma or supernatant proteins loaded in the
immunoblotting (Fig. 4b). In addition, we purified exo-
somes from the plasma of HCV and HS using a specific
anti-CD81 magnetic beads, followed by flow cytometric
analysis of the bead-coated exosomes using a phycoery-
thrin (PE)-labeled anti-human CD81 antibody. Again,
these magnetic bead-purified exosomes from both HS and
HCV plasma were enriched in CD81 tetraspanin (Fig. 4c).
To visualize the structure and identify the exosomal
marker CD81, we performed immuno-electron micro-
scopy (IEM) on the purified exosomes, which were stained
with or without mouse anti-huCD81 antibody, followed
by anti-mouse IgG gold particles (12 nm in diameter). As
shown in Fig. 4d, we observed exosome vesicles, ranging
from 30 to 90 nm (left panel without gold labeling), with
CD81-gold particles bound to their membrane surface
(right panel with gold labeling).
Since HCV E2 envelope protein binds human tetra-
spanin CD81 with high affinity, and CD81 is enriched in
exosomes released from cells including hepatocytes34,35,
we next sought to determine whether exosomes isolated
from the plasma of HCV-infected patients or culture
supernatants of HCV-infected hepatocytes contain HCV
RNA or proteins that may act as inducers of MDSC
development. To this end, we isolated the exosomes using
Fig. 3 Exosomes are taken up by myeloid cells and promote MDSC development. a Representative dot plots of flow cytometric analysis of the
uptake of CFSE-labeled exosomes by the purified myeloid cells. Isolated exosomes were labeled with CFSE, incubated with the purified CD33+
myeloid cells, followed by flow cytometric analysis for the uptake of CFSE-labeled exosomes. Cells incubated without exosomes served as control.
b Confocal microscopic analysis of the uptake of CFSE-labeled exosomes by CD33+ myeloid cells. Cells incubated without exosomes served as
negative control. A typical cell with bright light field, florescence field and merge is shown. c Representative dot plots showing the gating strategy for
flow cytometric analysis of CD14+CD33+HLA-DR− MDSCs. d Summary data of flow cytometric analysis of the MDSC frequencies in PBMCs exposed
to HS-Exo, HCV-Exo and SVR-Exo for 3 days. e Summary data of flow cytometric analysis of the TFR and TFH cell frequencies in PBMCs exposed to HS-
Exo, HCV-Exo and SVR-Exo for 3 days. f Summary data of flow cytometric analysis of the kinetic changes in monocytic myeloid cells and MDSCs in
PBMCs treated with HCV-Exo and HS-Exo in a time- and dose-dependent manner. Those with statistically significant fold changes of M-MCs and M-
MDSCs induced by HCV-Exo (normalized by HS-Exo) are marked as *P < 0.05 or **P < 0.01. g Induction of monocytic myeloid cells by exosomes
isolated from the supernatants of HCV-infected (Huh7R) and uninfected (Huh7) hepatocytes. The data were reproducible in three independent
experiments. *P < 0.05, **P < 0.01
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the sequential centrifugation method36 and performed
reverse transcription-polymerase chain reaction (RT-
PCR) for HCV RNA and western blot for HCV E1, E2 and
Core proteins. As shown in Fig. 4e, HCV RNA was found
in exosomes isolated from the plasma of HCV-infected
patients, but not in those who received DAA treatment
with SVR or from HS (upper panel). We also measured
the viral load in purified exosomes by real-time RT-PCR
and amplified 37–270 international unit (IU) per ml of
plasma-derived exosomes from HCV patients (lower
panel). As reported by other investigators36, this immu-
nosorting method does not allow quantification of the
exosomes purified out of the total plasma exosome pool,
and because we do not know what fractions of plasma-
derived exosomes are released by HCV-infected cells, it is
difficult to estimate how much HCV RNA is associated
with exosomes in patients’ plasma. In addition to exo-
somes derived from patient plasma, we isolated exosomes
by ultracentrifugation from the supernatants of HCV+/−
Huh7 cells. As shown in Fig. 4f upper panel, HCV RNA
was only detected in the exosomes isolated from the
supernatants of HCV-infected Huh7R cells, with a copy
number of 285,015 IU/ml supernatant-derived exosomes,
but not in those from non-infected Huh7 cells. Because
HCV virions and exosomes have very similar buoyant
densities in sucrose gradient, there was a concern that the
traditional ultracentrifugation method is insufficient for
separating pure exosomes free of virus contamination. To
Fig. 4 Characterization of exosomes isolated from HCV patient plasma and HCV-infected cells. a Identification of CD63, CD81 and HSP90
expressions in exosomes isolated from the plasma of HCV patients and HS (with exoEasy Maxi Kit) by immunoblotting. b Evaluation of CD63
concentration in the plasma and purified exosomes isolated from the same subject, or in the supernatant and enriched exosomes with exoEasy Maxi
Kit. The same amount of proteins were loaded in the immunoblotting. c Detection of CD81 expression in exosomes (purified by CD81-coated beads)
by flow cytometric analysis. d Electron microscope observation of exosomes. Exosomes isolated from the supernatant of HCV+/− Huh7 cells by
differential centrifugation were immuno-stained with or without anti-CD81 antibody, followed by secondary antibody labeled with 12 nm gold
particles, then subjected to IEM observation. Arrowed structures represent exosomes without gold labeling (left panel) and exosomes associated with
gold particles (right panel). Bars= 50 or 100 nm as indicated. e Detection of HCV RNA by RT-PCR in exosomes purified by sequential centrifugation
from HCV+/− subjects (upper panel) and quantification of their copy numbers in exosomes isolated from 1ml plasma of HCV-infected patients by
real-time RT-PCR. f Detection of HCV RNA by real-time RT-PCR in exosomes isolated by the centrifugation method from culture supernatants of
HCV+/− Huh7 cells. HCV RNA copy number, shown as IU/ml supernatant-derived exosomes, is shown in the upper panel. Repeated experiments by
RT-PCR measuring HCV RNA in exosomes purified by CD81-coated beads from the culture supernatant of HCV-infected (Huh7R) and -uninfected
(Huh7) hepatocytes are shown in the lower panel. g Detection of HCV Core protein in exosomes isolated from the plasma of HCV+/− subjects or from
the supernatants of HCV+/− Huh7 cells by exoEasy Maxi Kit followed by CD81-coated beads purification methods. Lower panel show exosomes
isolated from the supernatants of HCV+/− Huh7 cells by the sequential centrifugation method. Cell lysate from Huh7 and Huh7R hepatocytes served
as negative and positive controls. h Repeated experiments by RT-PCR measuring HCV RNA in CD33+ myeloid cells incubated with exosomes isolated
from the supernatants of HCV+/− Huh7 cells overnight
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overcome this limitation and to exclude other micro-
particles or free HCV contamination, we employed a
Total Exosome RNA and Proteins Isolation Kit followed
by a CD81-conjugated immune-magnetic bead isolation
method to purify exosomes from culture supernatants of
HCV-infected and -uninfected hepatocytes. As shown in
Fig. 4f lower panel, HCV RNA was detected in exosomes
purified from the supernatants of HCV-infected Huh7R
cells, but not in exosomes isolated from non-infected
Huh7 culture media. Similar to previous reports by other
investigators who failed to detect viral proteins in these
exosomes36, we also could not detect any HCV proteins in
exosomes isolated from the plasma of HCV patients or
the supernatant of HCV-infected Huh7 cells, either by
CD81-bead purification (upper panel) or by sequential
centrifugation isolation method (lower panel), although
HCV core protein could be detected in the cell lysates
from HCV+ Huh7 cells by western blotting (Fig. 4g). Also,
we could not detect β-actin or glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) RNA or their pro-
teins in exosomes by either isolation method. Since HCV
RNA-containing exosomes can trigger pDC innate
immunity37 and pDCs function as sentinels of viral
infection, predominantly via recognition of single-
stranded RNA by endosomal Toll-like receptors
(TLRs)46, we thus hypothesized that HCV RNA might
associate with TLRs in exosomes to be secreted by
hepatocytes into the circulation. However, while we
detected HCV RNA in the HCV-Exo, we could not detect
TLR-3, -7 and -9 in the HCV-Exo, perhaps due to the low
sensitivity of this detection method and/or very low levels
of HCV-associated TLR proteins in these purified
exosomes.
We next asked whether HCV-Exo could transfer viral
RNA into myeloid cells to drive MDSC differentiation. As
shown in Fig. 4h, real-time RT-PCR provided mechanistic
evidence that CD33+ myeloid cells contain HCV RNA
after incubation overnight with exosomes derived from
HCV-infected Huh7R cells, but not in myeloid cells
incubated with exosomes isolated from non-infected
Huh7 cells. These results suggest that the fusogenic
capabilities of exosomes could deliver HCV RNA into
myeloid cells and trigger MDSC induction.
HCV-Exo induce MDSC expansion through a miR-124-
mediated signaling pathway
CD81, scavenging receptor class B member I (SR-BI),
and apolipoprotein (ApoE) are important host receptors
for HCV entry and infection47. However, antibodies tar-
geting receptor-mediated entry of HCV into hepatocytes
confer limited therapeutic benefits48, raising the possibi-
lity that other mechanisms can mediate virus transmis-
sion. Recently, it has been reported that exosomes could
mediate CD81-, SR-BI- and ApoE receptor-independent
transmission of HCV infection38, which could explain in
part why neutralization antibodies or therapies targeting
host/viral protein interactions at the level of cell entry are
compromised and likely occur via cell-to-cell transmis-
sion by exosomes. While evidence suggests that exosomes
can transfer genetic materials between cells, their role in
immune dysregulation, particularly, in MDSC induction
remains obscure. Based on these studies, we first tested
whether the presence of anti-CD81, anti-SR-BI or anti-
ApoE antibodies would block the fusogenic effect of
exosomes on myeloid cells. To this end, we incubated
CD33+ myeloid cells with these antibodies or IgG control
for 2 h, respectively, then added PKH67-labeled HCV-Exo
into the cultures for 1 h, followed by flow cytometric
analysis of exosome association with myeloid cells. In this
case, CD33+ cells incubated with exosomes without
PKH67 labeling or with PKH67 labeling only served as a
negative control (NC) and a positive control (PC),
respectively. As shown in Supplementary Fig. S1a, we
found that anti-CD81, anti-SR-BI and anti-ApoE pre-
treatment could not block the exosome uptake by myeloid
cells. We then assessed whether these blocking antibodies
could functionally affect the exosome-induced MDSC
induction. To this end, 5 healthy PBMCs were pretreated
with these antibodies or IgG control for 2 h, then HCV-
Exo were added to the cultures for 3 days, followed by
flow cytometric analysis of CD33+ myeloid cells. As
shown in Supplementary Fig. S1b, while anti-SR-BI did
not change the frequency of myeloid cells in PBMCs in
the presence of HCV-Exo, anti-CD81 and anti-ApoE
pretreatment remarkably reduced the frequency of mye-
loid cells in PBMCs exposed to HCV-Exo. These results
were not in line with the data from the experiment of
blocking exosome uptake; we thus questioned whether
these decreases in CD33+ myeloid cells were due to
the effect of the blocking antibodies on PBMCs. To depict
the disparity shown in Supplementary Fig. S1a and b,
we incubated PBMCs with blocking antibodies in the
absence of HCV-Exo and cultured the cells under
the same condition. We observed the same decreases in
CD33+ myeloid cell frequencies in antibody (Ab)-treated
PBMCs (Supplementary Fig. S1c), suggesting anti-CD81
and anti-ApoE antibodies could alter the myeloid cell
behavior. Taken together, these data indicate that HCV-
Exo mediate a CD81-, SR-BI- and ApoE receptor-
independent effect on MDSC induction during viral
infection.
Using gene array and functional assays, we have pre-
viously shown that decline of miR-124 in myeloid cells
promotes Treg cell development during HCV infection;26
however, how HCV infection leads to miR-124 down-
regulation in myeloid cells remains unknown. Notably, we
did not observe any difference of miR-124 levels in HCV-
Exo compared to HS-Exo, suggesting that the observed
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decline of miR-124 expression in myeloid cells26 is not
due to its low level in exosomes secreted from HCV-
infected cells, but may be due to the effect of HCV-Exo on
myeloid cells. To further investigate the mechanisms of
HCV-Exo in MDSC induction, we incubated healthy
CD33+ myeloid cells for 3 days with exosomes purified
from the culture media of HCV-infected or non-infected
Huh7 cells, followed by real-time RT-PCR to measure
miRNA expression profiles. As shown in Fig. 5a, miR-124,
but not miR-125, was significantly inhibited in CD33+
myeloid cells by HCV RNA-containing exosomes isolated
from the supernatant of HCV-infected Huh7R when
compared to those exposed to exosomes derived from
Huh7 cells without HCV infection. To investigate whether
reconstitution of miR-124 in PBMCs can change the
ability of HCV-Exo to induce MDSC expansion, we
treated human PBMCs transfected with or without miR-
124 mimic or negative control for 3–5 days with exo-
somes isolated from HCV patients or HS, followed
by analysis of miR-124/miR-125 levels and MDSC fre-
quencies. As shown in Fig. 5b, compared to the cell-
s transfected with miR-NC, PBMCs transfected with
miR-124 mimic exhibited an increase in miR-124, but
not miR-125, level in CD33+ myeloid cells. PBMCs
incubated with HCV-Exo induced monocytic MDSC
(CD14+CD33+HLA-DR−) development compared to
those treated with HS-Exo. Importantly, reconstituting
PBMCs with miR-124 abrogated the effect of HCV-Exo in
inducing the expansion of MDSCs (Fig. 5c) and abolished
the induction of MDSCs by exosomes derived from the
culture supernatants of HCV-infected hepatocytes. In
conjunction with our previous studies, these new findings
suggest that HCV-infected hepatocytes can secrete HCV
RNA in the form of exosomes, and these HCV RNA-
containing exosomes can be taken up by monocytic
myeloid cells to trigger their differentiation into MDSCs
via inhibiting miR-124. These MDSCs, in turn, can pro-
mote the expansion of Foxp3+ Tregs, including TFR dif-
ferentiation, and thus regulate IFN-γ and IL-10
production in CD4+CXCR5+ T follicular cells, which are
important for viral persistence and vaccine non-
responsiveness during infection, as depicted in Fig. 6.
Discussion
We have previously shown that MDSCs expand during
chronic viral (HCV, HIV) infection and regulate T-cell
differentiation and functions20,25. We have also demon-
strated that a decline in miR-124 expression enhances
Foxp3+ Treg cell differentiation and inhibits effector T
(Teff) cell functions via regulating the signal transducer
and activator of transcription 3 (STAT-3) pathway26. Our
miRNA array analysis and RT-PCR assays show that miR-
124 is downregulated in MDSCs during HCV infection.
Bioinformatic analysis suggests that miR-124 may be
Fig. 5 HCV-Exo induce MDSCs through the miR-124-mediated signaling pathway. a miR-124 (upper panel) and miR-125 (lower panel)
expressions in CD33+ myeloid cells treated with exosomes isolated from the supernatants of HCV-infected (Huh7R) and -uninfected (Huh7)
hepatocytes. b Human PBMCs were treated with exosomes isolated from HS, with or without transfection of miR-124 mimic or miR-NC (negative
control) for 3 days, followed by RT-PCR analysis of miR-124 or miR-125 levels. Each symbol represents one HS PBMC to be treated (n= 9 in each
group). c MDSC inductions in healthy PBMCs treated with exosomes isolated from plasma of HS and HCV patients (n= 11 in each group) with the
centrifugation method, with or without transfection of miR-124 or miR-NC (n= 8 in each group), and cultured for 3 days, and MDSCs were analyzed
by flow cytometry
Wang et al. Cell Discovery  (2018) 4:51 Page 9 of 15
involved in the regulation of STAT-3, which is over-
expressed in MDSCs from HCV-infected patients26.
Notably, reconstitution of miR-124 decreases the levels of
STAT-3 as well as IL-10 and transforming growth factor-
β, which are also overexpressed in MDCSs and reduces
the frequencies of Foxp3+ Treg cells that are developed
during chronic HCV infection26. In this study, we further
demonstrate that: (1) chronic HCV infection is associated
with a decrease in TFH cells with relatively low IL-21
expression, and remarkably increased TFR cells with ele-
vated IL-10 production; (2) HCV-associated MDSCs can
inhibit the function of TFH cells via promoting the
induction and/or maintenance of TFR cells during chronic
HCV infection; (3) exosomes derived from the plasma of
HCV patients as well as HCV-infected hepatocytes con-
tain HCV RNA that can induce MDSC expansion, but
exosomes isolated from patients received antiviral treat-
ment with SVR do not harbor HCV RNA and cannot
induce MDSC development; (4) HCV-infected hepato-
cytes can secrete HCV RNA in the form of exosomes, and
these HCV RNA-containing exosomes can be taken up by
monocytic myeloid cells in a virus receptor-independent
way and regulate their differentiation into M-MDSCs via
inhibiting miR-124. These MDSCs then promote the
expansion of Foxp3+ Tregs, including TFH differentiation,
and thus inhibit TFH cell functions, including IFN-γ and
IL-10 secretion. These results reveal a novel paradigm
regarding the role of HCV-Exo in promoting the expan-
sion of MDSCs and Treg (TFR) cells as a mechanism of
inhibiting Teff (TFH) cell functions during chronic HCV
infection.
Exosomes are enriched in tetraspanins and have fuso-
genic capabilities27,28. They are formed by membrane
budding into the lumen of an endocytic compartment,
leading to the formation of multivesicular bodies (MVBs).
Fusion of MVBs to the plasma membrane leads to the
extracellular release of exosomes, a process similar to an
enveloped virus particle budding from the host cell sur-
face. Indeed, the budding of several enveloped viruses
(HCV, HBV and HIV) involves an endosomal sorting
complex required for transport (ESCRT), which is part of
the cellular machinery used to form MVBs49,50. Since
human tetraspanin CD81 binds the HCV envelope gly-
coprotein E2, exosomes may play an important role in the
cellular and extracellular trafficking of HCV particles. In
line with this, previous studies of the HCV life cycle
revealed that in the absence of CD81, HCV envelope
proteins are almost completely retained in the endo-
plasmic reticulum. When CD81 is present, a fraction of
HCV envelope proteins passes through the Golgi appa-
ratus, matures as it acquires complex sugars and is
extracellularly associated with exosomes36. It has also
been reported that Hrs, an ESCRT-0 component, is cri-
tical for assembling and budding of HCV through the
exosomal secretion pathway50. However, as other inves-
tigators have failed to detect HCV proteins in exosomes,
we also could not detect HCV E1, E2 and Core proteins in
exosomes isolated from plasma of HCV-infected patients
and supernatant of HCV-infected hepatocytes, using
either ultracentrifugation isolation method or purification
by immune capture of exosomes with beads coated with
anti-CD81 antibodies. This may be due to the small
amount of HCV mature/immature particles in exosomes
purified from the plasma or supernatant, and/or the
limited sensitivity of our detection methods. Nevertheless,
we found HCV RNA present in exosomes from both the
HCV patient plasma and the supernatants of HCV-
infected hepatocytes, but not in exosomes isolated from
HCV patients who received DAA treatment with SVR.
Importantly, exosomes are equipped to survive
Fig. 6 A schematic model for HCV-associated exosomes in promoting MDSC expansion to regulate T follicular cell differentiation and
function. HCV-infected hepatocytes can secrete HCV RNA in forms of exosomes, which are more resistant to neutralizing antibodies in the peripheral
blood. These HCV RNA-containing exosomes can be taken up by monocytic myeloid cells and promote MDSC expansion via inhibiting miR-124
expression which, in turn, regulates the differentiation of TFR cells along with increasing IL-10 production and suppression of IFN-γ secretion from TFH
cells. This paradigm represents a novel mechanism of immune dysregulation by HCV-Exo, leading to viral persistence and vaccine non-
responsiveness during chronic viral infection
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extracellularly to perform their functions, as suggested by
the finding that they contain CD55 and CD59 to protect
cell membrane-embedded materials from complement
attack51. We thus propose that “bona fide” HCV particles
replicate and exit the infected hepatocytes in the form of
exosomes, which then circulate and exploit their fuso-
genic capabilities to other cells, even in the presence of
complement and neutralizing antibodies. This may
explain, at least in part, the relative ineffectiveness of
neutralizing antibodies in blocking HCV infection, as
exosomes containing HCV RNA may fuse to uninfected
cells or replication-non-permissive bystander immune
cells in the presence of virus-specific antibodies.
While the exact physiological functions of exosomes
remain unclear, they have been implicated in transferring
materials (e.g., antigens, cytokines and chemokines,
mRNAs or miRNAs) among cells without direct cell-to-
cell contact29–31. Exosomes can fuse to various cell types,
given their content of several membrane proteins, such as
α4β1 integrins, ICAMs (intercellular adhesion molecules),
tetraspanins and MHC (major histocompatibility com-
plex)52. The potential physiological relevance of our
finding of HCV RNA transfer via exosomes is supported
by recent reports showing that exosome-mediated
cell–cell transmission of HCV RNA, miRNA and small
interfering RNA occurs between hepatocytes in vivo38,53,
that HCV RNA-containing exosomes are detected in the
plasma of chronically HCV-infected patients36 and that
pDCs are abundant in the HCV-infected liver and
respond normally to HCV-infected cells54,55.
The current concept of virus-induced innate immune
responses is that recognition of viral nucleic acids typi-
cally occurs within cells that are either productively
infected or have internalized viral particles. For example,
HCV has evolved a potent strategy that precludes type I
IFN induction by infected hepatocytes56,57. Recently, it
has been reported that short-range exosomes can transfer
HCV RNA from infected cells to uninfected hepatocytes
or pDCs and trigger innate immunity37–39. The exosomal
viral RNA transfer is independent of CD81-, SR-BI- and
ApoE receptor-mediated mechanisms, but depends on the
ESCRT machinery and on Annexin A2, an RNA-binding
protein involved in membrane vesicle trafficking, and is
suppressed by exosome release inhibitors. Additionally,
purified concentrated HCV RNA-containing exosomes
were sufficient to transfer HCV infection in hepatocytes
and to activate interferon responses in pDC immune
cells37–39. In this study, we demonstrated that HCV-Exo
can be taken up by monocytic myeloid cells in a virus
receptor-independent manner to inhibit miR-124
expression in monocytic myeloid cells and promote
their differentiation into MDSCs, which in turn, regulate
TFR and TFH differentiation and functions. As depicted in
Fig. 6, our current results illustrate a previously
unrecognized mechanism of MDSC expansion and TFR
regulation, in which the vesicular transport machinery in
HCV-infected cells produces viral RNA-loaded, immu-
nomodulatory exosomes. This may serve as a viral strat-
egy to evade pathogen sensing, as well as a host strategy to
induce an unopposed innate-to-adaptive immune
response in replication-non-permissive bystander cells.
Our findings have potential implications in relation to
HCV-induced immune dysregulation and, most impor-
tantly, vaccine responses. For example, we and others have
previously reported poor vaccine responses in virally
infected individuals58–61. We have also shown that
chronically HCV-infected individuals exhibit premature
T-cell aging, contributing to the poor HBV vaccine
response in HCV- and/or HIV-infected individuals62,63. It
is well known that cellular and humoral immunity wanes
with age64, although the exact mechanisms for this process
remain unclear. A recent report, however, revealed that
defective T cell-dependent B-cell responses associated
with aging can result from an overabundance of fully
suppressive TFR cells and impaired TFH cell functions
65.
Notably, inhibitory TFR cells expand with age, leading to
higher TFR/TFH ratios, and these impaired TFH and
increased TFR cells lead to diminished B-cell responses
in the elderly. In this study, we further demonstrate
that HCV-Exo-induced MDSCs contribute to an altered
TFR/TFH cell ratio and IL-10/IFN-γ production, suggesting
that chronic viral infection-caused premature immune
aging recapitulates the nature aging process in the elderly.
This may underpin, at least in part, the mechanism of
vaccine non-responsiveness in virally infected individuals.
In summary, we have shown that HCV-associated
exosomes contain immunomodulatory viral RNA and
serve as vehicles to transmit HCV RNA from infected
cells to bystander immune cells and are sufficient to
induce MDSC expansion via inhibiting miR-124 to reg-
ulate T follicular cell differentiation and functions. Our
results illustrate an unopposed mechanism of viral
immune evasion: i.e., exosomal package and secretion
of viral RNA from infected cells may represent a
perfect pathogen–host interaction and immune evasion
machinery that serves as a viral strategy to transmit
infection in a cell contact-independent manner as well
as a host strategy to induce innate-to-adaptive
immunity by a viral replication-non-permissive bystan-
der mechanism. Further characterization of the virus-
associated exosomes in regulation of the host immunity
will enhance our understanding of the mechanisms
of virus persistence and vaccine failure in chronic viral
infection in humans. Delineating these mechanisms have
clinical implications in designing prophylactic/therapeutic
vaccines to combat HCV and other chronic viral infec-
tions, and may also have broad impact on immunocom-
promised hosts, such as those with immunosuppressive
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The study protocol was approved by an institutional
review board at East Tennessee State University and
James H. Quillen VA Medical Center (ETSU/VA IRB,
Johnson City, TN). The study subjects were composed of
three populations: 98 chronically HCV-infected patients
(70% genotype 1, 30% genotype 2 or 3, viral load range
from 21,000 to 48,000,000 IU/ml), 10 HCV-resolved
patients after DAA treatment with SVR and 72 age-
matched HS. Written informed consent was obtained
from all participants. HCV-infected patients were
HCV RNA positive, prior to antiviral treatment. Age-
matched HS, derived from Physicians Plasma Alliance
(PPA), Gray, TN, were negative for HBV, HCV and HIV
infection.
Cell isolation, culture and flow cytometric analysis
PBMCs were isolated from whole blood by Ficoll den-
sity gradients (GE Heathcare, Piscataway, NJ). CD33+
myeloid cells were further isolated or depleted, depending
on the experimental requirements, from PBMCs using the
CD33+ Cell Isolation Kit and a MidiMACS™ Separator
(Miltenyi Biotec Inc., Auburn, CA). The isolated cells
were cultured in RPMI 1640 medium containing 10% fetal
bovine serum (FBS; Atlanta Biologicals, Flowery Branch,
GA), 100 IU/ml penicillin and 2mM L-glutamine
(Thermo Scientific, Logan, Utah) at 37 °C and 5% CO2
atmosphere. Co-culture of cells with or without exosomes
was carried out as described in the Results. Phenotypic
and intracellular cytokine analyses of PBMCs or co-
cultured cells, with or without stimulation, were carried
out as previously reported25,26, using the following
reagents: anti-CD4-FITC, anti-CXCR5-AF 647, anti-
Foxp3-PE-Cy5, anti-IL-21-PE, anti-IL-10-PE, anti-
IFN-γ-PE, anti-CD33-APC, anti-CD14- PerCP-Cy5.5,
anti-HLA-DR-FITC and anti-CD81-PE, or isotype control
antibodies (BD Bioscience, San Jose, CA). To see if exo-
somes can be taken up by myeloid cells, CD33+ cells were
incubated with the CFSE-labeled HCV-Exo for 1 h; after
intensive washing, flow cytometry was employed to
examine the fluorescence signal within the cells. For
exosome uptake blocking assays, the purified CD33+
myeloid cells were incubated with blocking antibodies
(mouse anti-CD81, sc-23962, Santa Cruz; rabbit anti-SR-
BI, ab-525629, Abcam; Goat anti-ApoE, AB947, EMD
Milipore) and isotype control (mouse IgG 553447, BD;
rabbit IgG sc-2027, Santa Cruz; goat IgG 31245, Ther-
moFisher) for 2 h, respectively; PKH67 (MINI67, Sigma)-
labeled HCV-Exo were added into the culture for 1 h.
Cells cultured with HCV-Exo without labeling or with
PKH67-labeled HCV-Exo only serve as NC or PC. To
functionally analyze the effect of blocking antibodies on
HCV-Exo-mediated myeloid cell differentiation, PBMCs
were incubated with the blocking antibodies and control
IgG for 2 h, respectively, and cultured in the presence or
absence of HCV-Exo for 3 days, followed by flow cyto-
metric analysis for the frequency of CD33+ myeloid cells
in PBMCs. The cells were acquired on an AccuriTM C6
flow cytometer (BD, Franklin Lakes, NJ) and analyzed
using FlowJo software (Tree Star, Inc., Ashland, OR). The
fluorescence minus one (FMO) strategy was used to
determine background levels and to adjust multicolor
compensation for cell gating.
Exosome isolation and purification
Plasma was isolated from 50ml of blood from the
research subjects and filtered to exclude particles larger
than 0.8 μm using sytinge filters (Millipore® Millex®-AA
Cat. No: SLAA033SS, Billerica, MA). Supernatants of the
culture media from Huh7 cells with or without HCV
infection were also filtered in the same way. Exosomes
were isolated from 4ml of filtered plasma or supernatant
with exoEasy Maxi Kit (QIAGEN Cat. No. 76064) per the
manufacturer’s instructions. To further purify exosomes
and exclude other microparticles or free HCV con-
tamination, pre-enriched exosomes were incubated with
Mix CD81 beads (Invitrogen Cat. No: 00353003) at 4 °C
overnight, and then the bead-bound exosomes were
purified with magnetic separator according to the proto-
col of the manufacturer. Additionally, exosomes were also
isolated by the differential centrifugation method as pre-
viously reported36. In brief, plasma from HCV+/− subjects
or culture media from HCV+/− Huh7 cells were cen-
trifuged at 200 × g for 10 min (P1), the supernatants were
collected and centrifuged twice at 500 × g for 10 min (P2),
the second supernatants were collected and centrifuged
twice at 2000 × g for 15 min (P3), the third supernatants
were collected and centrifuged once at 10,000 × g for
30 min (P4), the fourth supernatants were collected and
centrifuged once at 70,000 × g for 60 min (P5), and the
precipitates (exosomes) were resolved in 300 μl distilled
water for further experiments.
Western blot
Exosomes purified by CD81-bound beads were lysed
with RIPA buffer with sonication. Western blot was car-
ried out as described previously using anti-CD63
(Santa Cruz Biotechnology Cat. No: sc-5275, Santa
Cruz, CA), anti-CD81 (Santa Cruz Cat. No: sc-9185, Santa
Cruz, CA) and anti-HCV core (ThermoFisher, C7-50,
Waltham, MA) primary antibodies, followed by a horse-
radish peroxidase-conjugated secondary antibody (Cell
Signaling)25,26. Membranes were stripped and re-probed
with anti-GAPDH antibody (Santa Cruz Biotechnology)
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as a loading control. The proteins were visualized
using the Amersham ECL Prime Western Blotting
Detection Reagents (GE Healthcare Biosciences, Pitts-
burgh, PA) and Bio-Rad chemiDocMP imaging system
(Philadelphia, PA).
Confocal microscopy and IEM
CD33+ myeloid cells were isolated and cultured with
CFSE-labeled HCV-Exo for 1 h, followed by examination
of fluorescence signal with confocal laser-scanning
inverted microscope (Leica Confocal Model TCS sp8,
Germany). To observe the structure of exosomes, the
purified exosomes (P5 preparation) were seeded on
carbon-coated Formvar nickel grids (EM Sciences, Hat-
field, PA) and left to adsorb onto grids at 4 °C overnight,
fixed with EM-grade 2% paraformaldehyde (EM Sciences,
Hatfield, PA) and 0.1% glutaraldehyde (EM Sciences,
Hatfield, PA) at 4 °C for 1 h, blocked with 2% cold fish
gelatin (Sigma, St. Louis, MO)/0.1% bovine serum albu-
min/phosphate-buffered saline (PBS) for 30min at room
temperature and incubated with 50 µg/ml mouse anti-
human CD81 antibody (BD Pharmingen, San Jose, CA)
for 2 h at room temperature. After washing with PBS, the
exosomes were incubated with 1:40 diluted 12 nm Col-
loidal Gold-AffiniPure Goat anti-mouse IgG (Jackson
ImmunoResearch Laboratories, West Grove, PA) for 30
min at room temperature. After washing with PBS, the
grids were stained with 1% aqueous uranyl acetate before
observation with a Zeiss Auriga 40 operating in STEM
mode at 30 kV electron microscope.
Real-time PCR
RNA was isolated from purified exosomes or CD33+
cells incubated with exosomes using Total Exosome RNA
and Proteain Isolation Kit (Cat. No. 4478545, Invitrogen).
RNA quality and quantity were analyzed using a
BioPhotometer spectrophotometer ultraviolet–visible.
Reverse transcription was performed using High-Capacity
Complementary DNA Reverse Transcription Kits
(Applied Biosystems, Foster City, CA). An HCV Genesig®
Standard Kit was employed to perform real-time PCR
measuring 5’ untranslated region of HCV genome. HCV
RNA copy numbers were calculated based on the plasma
or supernatant volume to be used for isolation of exo-
somes and the standard curve of the positive control
according to instructions of the manufacturer (Pri-
merdesignTM Ltd, Chandler’s Ford SO53 4DG, UK).
Quantifications of miR-124, miR-125 and miR-29 levels
were completed using Power SYBR® Master Mix Kit (Cat.
No. 4367659, Applied Biosystem) on CFX96TM Real-
time PCR Detection System (Bio-Rad Laboratories, Inc.
Hercules, CA) according to the protocols of the manu-
facturers. After agarose gel electrophoresis, image was
captured using Bio-Rad chemiDocMP imaging system
(Philadelphia, PA). miRNA levels were quantified with the
2−ΔΔct relative quantification method, normalized to
U61 small nuclear RNA (SNORD61).
miRNA transfection
PBMCs of HCV patients were transfected with 30 pmol
of mirVana microRNA mimic for miR-124 or negative
control #1 (Life technologies, Grand Island, NY) using the
Human Monocyte Nucleofector Kit and Nucleofector I
Device (Lonza, Allendale, NJ). We could achieve 60%
transfection efficiency with fluorescence-labeled miRNAs
with this method26. The transfected cells were cultured in
10% FBS Iscove's modified Dulbecco's medium in the
presence of exosomes isolated from plasma of HCV
patients or HS and from supernatants of HCV-infected or
-uninfected hepatocytes (Lonza, Allendale, NJ) for 3 and
5 days, followed by immune staining for the frequency of
MDSCs as described above.
Statistical analysis
The parametric data were presented as mean ± SEM.
Association between MDSCs and TFR or TFH was ana-
lyzed based on their frequencies in peripheral blood by
Pearson's correlation. Comparisons between groups were
made by one-way analysis of variance using Prism version
5. One-tail paired t-test was used to compare two groups
with transfection by miR-124 mimic and negative control.
The nonparametric data were presented as median and
analyzed by one-tail Mann–Whitney test. P < 0.05 or P <
0.01 were considered significant or very significant,
respectively.
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